Navigation Links
Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA
Date:12/14/2009

Staccato system with loxapine, a drug belonging to the class of compounds known generally as antipsychotics. Loxapine is currently available in an oral formulation in the United States for the management of the manifestations of schizophrenia. The Staccato system is a hand-held, chemically-heated, single-dose inhaler that delivers a pure drug aerosol to the highly vascularized tissues of the deep lung.

As an easy-to-use, patient-controlled, and highly reliable therapeutic that provides rapid reduction in agitation, the Company believes that AZ-004 meets the three key attributes for the treatment of acute agitation as specified in the American Association of Emergency Psychiatrists' Expert Consensus Guidelines for the Treatment of Behavioral Emergencies: speed of onset, reliability of medication delivery and patient preference.

Conference Call Information

Alexza will host a conference call tomorrow morning, December 15, 2009, at 8:30 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call and replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=P3WV9ALJV.

To access the live conference call via phone, dial 888-680-0860. International callers may access the live call by dialing 617-213-4852. The reference number to enter the call is 29185934.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
3. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
4. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
5. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
6. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
7. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
8. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
9. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... and VIENNA , July 31, 2014 ... press conference in New York results ... vaccine against Parkinson,s disease. PD01A is the first therapy against ... clinical testing. The Michael J. Fox Foundation for ... million grant, and presented at the press conference on the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... CO (PRWEB) August 01, 2014 According to ... onto the Internet do so in search of information, and ... website, those in search of information and resources on insurance ... , “We're excited to take this next step in the ... DCInsurers Colorado Springs - Commercial Insurance Resources office. ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , a ... be recognized as a 2014 Best of Home Care Employer ... providers who rank in the top 50th percentile in one ... conducted by Home Care Pulse. , “The Best of ... best of the best!” says Home Care Pulse Founder and ...
(Date:8/1/2014)... Ticket Down is a reputable source for ... in Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; Cross Creek ... FL. Luke Bryan is currently out on his summer “That’s ... Swindell. Bryan is responsible for one of the most popular ... year, just because the summer is over doesn’t mean that ...
(Date:8/1/2014)... Researchers and doctors at the Institute of Bioengineering ... National Cancer Centre Singapore (NCCS) have co-developed the ... and survival outcomes in kidney cancer patients. This ... , the world,s top urology journal. , ... Ying, "By combining our expertise in molecular diagnostics ...
Breaking Medicine News(10 mins):Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3
... World Health Organization (WHO), is calling for renewed vigilance against ... Korea, Hong Kong, Indonesia and Vietnam have been reported. There’s ... was probably due to a mutated H5N1 virus that could ... pandemic is overdue and could happen during the winter months. ...
... come out with findings from a study that indicates ... celexa in combating// depression. ,Dr. Fran?ois Lespérance, ... colleagues published their findings in this week’s edition of ... ,The drug celexa, which goes by the generic name ...
... Bilcare, a leading research-based pharmaceutical packing solution ... with Honeywell//, a UK-based pharma packaging firm, ... pharmaceutical sector. ,"The partnership with Honeywell's ... provide state-of-the-art materials for ensuing safety of ...
... maternal DNA in the blood of around 20% of children ... also seemed to help in producing insulin, which is not ... to restore damaged tissue in the pancreas. They also found ... immune system. ,During pregnancy, stem cells of ...
... the high prevalence of HIV/AIDS in Karnataka and hoping to ... Kumaraswamy will spend Tuesday night in the hut of a ... in Bagalkot district, 600 km from the state capital Bangalore ... around 11 p.m. and spend the night in the house ...
... coffee could help cure baldness as caffeine blocks the effects ... ,Tobias Fischer of the University of Jena in Germany took ... hair loss. He extracted hair follicles and placed them in ... ,The samples were left in the laboratory for ...
Cached Medicine News:Health News:Are We Prepared for Flu Pandemic? 2Health News:Citalopram, a Boon in Treating Depressed Heart Patients 2Health News:Karnataka Chief Minister to Spend Night With HIV Positive Family 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: